# Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

> **NCT04438096** · PHASE2 · UNKNOWN · sponsor: **CVI Pharmaceuticals** · enrollment: 200 (estimated)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** 100 mg
- **DRUG:** 200 mg
- **DRUG:** 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04438096
- **Lead sponsor:** CVI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-15
- **Primary completion:** 2021-12-15
- **Final completion:** 2022-03-15
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04438096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04438096, "Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04438096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*